Biontech defends price offer to EU policy


Biontech founder Ugur Sahin has become involved in the image-Zeitung resisted the impression that his company initially offered the EU the corona vaccine at a very high price. Sahin said, “It was early, mid-June, and it was our first price calculation with a large number of unknowns.” In fact, the “confidential” classified offer dates from June 24th, is several pages strong and justifies the price in detail.

It was submitted to the EU by the pharmaceutical company Pfizer on behalf of Biontech and Pfizer. Specifically, Pfizer / Biontech are offering the EU 500 million vaccine doses at a price of 54.08 euros.  The  offer literally states: “Based on our agreement that the estimated number of vaccine doses that the Commission plans to reserve (500 million), the price is 54.08 euros per dose, which is the highest percentage discount that has been offered to any advanced economy anywhere in the world. “


 The  phrase also suggests that corporate pricing had been going on for some time. Finally, advance payments of 3.50 euros per dose are mentioned, which are due immediately upon conclusion of the contract (“advance payment”). Sahin now emphasizes towards the imagethat at the time of the offer one could not yet have known “how exactly the production can be scaled” and also not “how the production processes and costs will be exactly”.

“Adding the trillion euro economic impact to a traditional cost-benefit model results in a price that would be unreasonable during a global pandemic”

NDR, WDR and Southgerman newspaper confronted Biontech with the sale offer on Tuesday of this week and asked, among other things, how the price of 54.08 euros was explained. ©

 The  company had not replied that this should have been an “initial price calculation”, nor that the production costs should have been unclear at the time.


 The  company had merely stated: “©

 The  price of the vaccine depends on various factors and is in a certain range for all countries with higher incomes. For countries with lower incomes, the price will be adjusted accordingly.”

Sahin left a request for a discussion about the high price offer to the EU unanswered this week. In fact, in their letter to the EU, Pfizer / Biontech had justified the price with various arguments, such as that they had “financed research and development entirely themselves” and that the corona pandemic was causing enormous economic damage worldwide. “Adding the trillion-euro economic impact to a traditional cost-benefit model results in a price that would be unreasonable during a global pandemic,” the offer said. Only then does the required sum of 54.08 euros per vaccine dose follow. ©

 The  image further quotes in its report an anonymous source “from circles of the federal government”, which allegedly said that it was clear to everyone that the offer from June was “a water level report”. ©

 The re is no proof of this and Biontech / Pfizer had not presented it that way before.

As SZ, NDR and WDR reported, Pfizer / Biontech agreed with the EU Commission on a final price of 15.50 euros in the summer and the USA also had 100 million vaccine doses in July at a price of 19.50 US dollars (16 euros) ordered.

[ source link ]

Biontech defends price offer policy


Please enter your comment!
Please enter your name here